The tagging detector of the CP-violation experiment NA48 at CERN Bergauer, H.; Blümer, H.; Calvetti, M. ...
Nuclear instruments & methods in physics research. Section A, Accelerators, spectrometers, detectors and associated equipment,
12/1998, Letnik:
419, Številka:
2-3
Journal Article
Recenzirano
Odprti dostop
The CP-violation experiment NA48 at CERN aims at measuring direct CP-violation in the decays of neutral kaons into π+π− and π0π0. The experiment uses simultaneous, almost collinear beams of neutral ...KL0 and KS0 mesons, which are produced on two different targets. KS0 events are “tagged” by measuring the times of the protons that fly towards the KS0 production target. In order to sustain the high rate of 107protons/s in this beam without suffering from too many pile-up events, the detector consists of 24 separate scintillators (12 horizontal and 12 vertical), each of which sees only a small fraction of the beam. Their signals are digitized by specially developed 1GHz FADCs. The exact time of a pulse is established offline by a fit procedure. The detector and its electronics have been successfully used during test beams in 1994–1996 and during the first physics run of NA48 in 1997. The inefficiency of the detector has been measured to 2×10−4. Sources of background have been identified to allow for off-line correction. The mechanical setup of the detector, the 1GHz FADC and results from the test and data runs are presented.
An 8-bit 1-GHz Flash-ADC module has been developed for the tagging system of the CP-violation experiment NA48 at CERN. The module contains two independent channels with 500 MHz sampling rate, which ...can be interleaved to obtain one channel with an effective sampling rate of 1 GHz. Both FADC chips run continuously and data samples are stored for 524 μs in a ringbuffer memory until they are overwritten by new data. During their “lifetime” data can be extracted from the ringbuffer without disturbing the write cycles. The module fits into a VXI-D crate and uses the VME bus. The design, construction, operation and performance of this module are presented.
An FPGA-based sigma-delta audio DAC Kulka, Z.; Lewandowski, M.
New Trends in Audio and Video / Signal Processing Algorithms, Architectures, Arrangements, and Applications SPA 2008,
2008-Sept.
Conference Proceeding
This paper presents a sigma-delta audio digital-to-analog converter (DAC) implemented on a single field programmable gate array (FPGA) for non-commercial application. The simulations' results of the ...digital interpolation filter and digital sigma-delta modulator are shown. The results of an FPGA-based hardware implementation will be obtained and presented soon.
Based on its mechanism of action, PARP inhibitor therapy is expected to benefit mainly tumor cases with homologous recombination deficiency (HRD). Therefore, identification of tumor types with ...increased HRD is important for the optimal use of this class of therapeutic agents. HRD levels can be estimated using various mutational signatures from next generation sequencing data and we used this approach to determine whether breast cancer brain metastases show altered levels of HRD scores relative to their corresponding primary tumor.
We used a previously published next generation sequencing dataset of 21 matched primary breast cancer/brain metastasis pairs to derive the various mutational signatures/HRD scores strongly associated with HRD. We also carried out the myChoice HRD analysis on an independent cohort of 17 breast cancer patients with matched primary/brain metastasis pairs.
All of the mutational signatures indicative of HRD showed a significant increase in the brain metastases relative to their matched primary tumor in the previously published whole exome sequencing dataset. In the independent validation cohort, the myChoice HRD assay showed an increased level in 87.5% of the brain metastases relative to the primary tumor, with 56% of brain metastases being HRD positive according to the myChoice criteria.
The consistent observation that brain metastases of breast cancer tend to have higher HRD measures may raise the possibility that brain metastases may be more sensitive to PARP inhibitor treatment. This observation warrants further investigation to assess whether this increase is common to other metastatic sites as well, and whether clinical trials should adjust their strategy in the application of HRD measures for the prioritization of patients for PARP inhibitor therapy.
Biological dosimetry enables individual dose reconstruction in the case of unclear or inconsistent radiation exposure situations, especially when a direct measurement of ionizing radiation is not or ...is no longer possible. To be prepared for large-scale radiological incidents, networking between well-trained laboratories has been identified as a useful approach for provision of the fast and trustworthy dose assessments needed in such circumstances. To this end, various biodosimetry laboratories worldwide have joined forces and set up regional and/or nationwide networks either on a formal or informal basis. Many of these laboratories are also a part of global networks such as those organized by World Health Organization, International Atomic Energy Agency or Global Health Security Initiative. In the present report, biodosimetry networks from different parts of the world are presented, and the partners, activities and cooperation actions are detailed. Moreover, guidance for situational application of tools used for individual dosimetry is given.
We compared levels of protein and mRNA expression of three members of the claudin (CLDN) family in malignant breast tumours and benign lesions.
Altogether, 56 sections from 52 surgically resected ...breast specimens were analyzed for CLDN1, CLDN3 and CLDN4 expression by immunohistochemistry. mRNA was also analyzed using real-time PCR in 17 of the 52 cases.
CLDNs were rarely observed exclusively at tight junction structures. CLDN1 was present in the membrane of normal duct cells and in some of the cell membranes from ductal carcinoma in situ, and was frequently observed in eight out of nine areas of apocrine metaplasia, whereas invasive tumours were negative for CLDN1 or it was present in a scattered distribution among such tumour cells (in 36/39 malignant tumours). CLDN3 was present in 49 of the 56 sections and CLDN4 was present in all 56 tissue sections. However, CLDN4 was highly positive in normal epithelial cells and was decreased or absent in 17 out of 21 ductal carcinoma grade 1, in special types of breast carcinoma (mucinous, papillary, tubular) and in areas of apocrine metaplasia. CLDN1 mRNA was downregulated by 12-fold in the sample (tumour) group as compared with the control group using GAPDH as the reference gene. CLDN3 and CLDN4 mRNA exhibited no difference in expression between invasive tumours and surrounding tissue.
The significant loss of CLDN1 protein in breast cancer cells suggests that CLDN1 may play a role in invasion and metastasis. The loss of CLDN4 expression in areas of apocrine metaplasia and in the majority of grade 1 invasive carcinomas also suggests a particular role for this protein in mammary glandular cell differentiation and carcinogenesis.
PDF
